PharmaVentures Podcast Series, Edition 2

How Your Pricing and Reimbursement Strategy Affects Your Deal Making Success

Hosted by Adrian Dawkes

Listen as PharmaVentures’ Pricing and Market Access expert, Ralph Hughes, recommends elements of a robust plan to help you achieve the best pricing and market access for your drug, and to give you the increased confidence to strengthen your position during deal making negotiations.

If you would prefer to read the transcript of the podcast please email: enquiries@pharmaventures.com

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

About the Interviewee:

Ralph Hughes is a Vice President at PharmaVentures with experience in Pricing and Market Access and Commercial and Business Development.

He has held various roles in the pharmaceutical industry. For Mundipharma, he developed the commercial and market access strategy for development and launch assets. At Pfizer, he developed market access and pricing strategies across the globe and across multiple disease areas for both early, late stage and in-market assets. He has delivered marketing campaigns, global forecasts, HTAs, pricing strategies, real world data studies, and economic models; through this, Ralph has a deep understanding of what it takes to commercialise an asset in the pharmaceutical industry. He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine and a BSc in Biomedical Sciences from Newcastle.

PharmaVentures Podcast Series, Edition 1

How to Acquire Companies or Assets Successfully: listen to see how you can improve your buy side and in-licensing activities

Hosted by Adrian Dawkes

In this podcast, PharmaVentures’ deal experts discuss the process of helping clients in the life sciences industry acquire or license assets or rights in specific markets or whole companies.

What does this podcast address?

• Why do pharmaceutical companies in-license and buy new assets?
• How does the process work?
• How will you know if it’s a good or a bad asset?
• What is the benefit of using advisors?
• What advice should you heed if you are thinking about embarking on acquiring or licensing an asset?

If you would prefer to read the transcript of the podcast please email: enquiries@pharmaventures.com

About the Presenter:

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

About the Interviewees:

Kyriakos Tzafestas is a Director at PharmaVentures.

Prior to joining PharmaVentures, Kyriakos was a life sciences consultant working with biotech companies and early-stage technologies on projects encompassing market analysis, competitive intelligence, opportunity assessment, commercialisation roadmaps, patent landscaping, valuations, and business development for research collaborations and licensing opportunities. Before commencing his professional career, Kyriakos completed a Master of Biotechnology (Distinction) at the University of Glasgow and obtained a PhD in Molecular Biology from the University of York.

Ross Jenkins is a Senior Analyst at PharmaVentures with previous experience in diagnostic start-ups and commercialisation.

Prior to joining PharmaVentures, Ross worked at a multiplex immune-diagnostic start-up in New Zealand focused on both human and animal health. During this time, he was involved across all areas of the business from communications, manufacturing, quality/regulatory affairs, and market analysis. Ross holds a BSC(Hons) in Biotechnology and, a PGDip and Masters in Bioscience Enterprise from the University of Auckland.